Sartorius snaps up Polyplus

Life sciences firm Sartorius has agreed to buy French company Polyplus for $2.6 billion. The deal, which Sartorius signed via subgroup Sartorius Stedim Biotech, brings nucleic acid delivery know-how into the firm’s portfolio. Polyplus also brings DNA vector design and plasmid engineering capabilities with it, gained in its own acquisitions in 2022. “In the dynamically growing market for cell and gene therapies, viral vectors are needed to deliver the genes of interest into cells. The development pipeline of such therapies has been growing strongly and more and more are reaching major milestones,” Sartorius Stedim Biotech’s CEO René Fáber says in a statement.